JP2011520915A5 - - Google Patents

Download PDF

Info

Publication number
JP2011520915A5
JP2011520915A5 JP2011509762A JP2011509762A JP2011520915A5 JP 2011520915 A5 JP2011520915 A5 JP 2011520915A5 JP 2011509762 A JP2011509762 A JP 2011509762A JP 2011509762 A JP2011509762 A JP 2011509762A JP 2011520915 A5 JP2011520915 A5 JP 2011520915A5
Authority
JP
Japan
Prior art keywords
alkyl
pyran
tetrahydro
cyclopropylsulfonyl
propanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011509762A
Other languages
English (en)
Japanese (ja)
Other versions
JP5513492B2 (ja
JP2011520915A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/044190 external-priority patent/WO2009140624A2/en
Publication of JP2011520915A publication Critical patent/JP2011520915A/ja
Publication of JP2011520915A5 publication Critical patent/JP2011520915A5/ja
Application granted granted Critical
Publication of JP5513492B2 publication Critical patent/JP5513492B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011509762A 2008-05-16 2009-05-15 グルコキナーゼ活性剤 Expired - Fee Related JP5513492B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5405208P 2008-05-16 2008-05-16
US61/054,052 2008-05-16
US10837008P 2008-10-24 2008-10-24
US61/108,370 2008-10-24
PCT/US2009/044190 WO2009140624A2 (en) 2008-05-16 2009-05-15 Glucokinase activators

Publications (3)

Publication Number Publication Date
JP2011520915A JP2011520915A (ja) 2011-07-21
JP2011520915A5 true JP2011520915A5 (enExample) 2012-07-12
JP5513492B2 JP5513492B2 (ja) 2014-06-04

Family

ID=41076813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011509762A Expired - Fee Related JP5513492B2 (ja) 2008-05-16 2009-05-15 グルコキナーゼ活性剤

Country Status (27)

Country Link
US (4) US8563730B2 (enExample)
EP (1) EP2294053B1 (enExample)
JP (1) JP5513492B2 (enExample)
KR (1) KR20110018366A (enExample)
CN (1) CN102105451B (enExample)
AR (1) AR071811A1 (enExample)
AU (1) AU2009246167B2 (enExample)
BR (1) BRPI0912802A2 (enExample)
CA (1) CA2724116A1 (enExample)
CL (1) CL2009001203A1 (enExample)
CO (1) CO6321274A2 (enExample)
CR (1) CR11827A (enExample)
DO (1) DOP2010000351A (enExample)
EA (1) EA018988B1 (enExample)
EC (1) ECSP10010688A (enExample)
GE (1) GEP20135783B (enExample)
IL (1) IL209062A (enExample)
MA (1) MA32391B1 (enExample)
MX (1) MX2010012298A (enExample)
MY (1) MY152749A (enExample)
NZ (1) NZ589084A (enExample)
PE (2) PE20091901A1 (enExample)
SG (1) SG190625A1 (enExample)
TW (1) TWI445707B (enExample)
UY (1) UY31830A (enExample)
WO (1) WO2009140624A2 (enExample)
ZA (1) ZA201007975B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2516290C2 (ru) 2007-08-27 2014-05-20 Басф Се Пиразольные соединения и их использование в способе борьбы с беспозвоночными вредителями, в способе защиты материала размножения растений, в способе лечения или защиты животных от инвазии или инфицирования, в материале размножения растений и сельскохозяйственные композиции, содержащие пиразольные соединения
WO2009099734A1 (en) * 2008-02-05 2009-08-13 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
TWI445707B (zh) 2008-05-16 2014-07-21 Takeda California Inc 葡萄糖激酶活化劑
BRPI0917705A2 (pt) 2008-08-27 2016-02-16 Takeda Pharmaceutical composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
GEP20135793B (en) * 2008-09-11 2013-03-25 Pfizer Heteroaryls amide derivatives and their use as glucokinase activators
EA020661B1 (ru) 2008-09-24 2014-12-30 Басф Се Пиразольные соединения для борьбы с беспозвоночными вредителями
WO2011003793A1 (en) 2009-07-06 2011-01-13 Basf Se Pyridazine compounds for controlling invertebrate pests
JP2012532176A (ja) 2009-07-06 2012-12-13 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物系害虫防除用ピリダジン化合物
WO2011009804A2 (en) 2009-07-24 2011-01-27 Basf Se Pyridine derivatives compounds for controlling invertebrate pests
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5909482B2 (ja) 2010-03-31 2016-04-26 ザ スクリプス リサーチ インスティテュート 細胞の再プログラム
SMT201800140T1 (it) 2010-05-26 2018-05-02 Vtv Therapeutics Llc Uso di metformina in conbinazione con un attivatore della glucochinasi e composizioni comprendenti metformina e attivatore della glucochinasi
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP2013544787A (ja) 2010-10-13 2013-12-19 タケダ カリフォルニア インコーポレイテッド アザインダゾール誘導体の調製方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG11201406987UA (en) 2012-05-17 2014-12-30 Transtech Pharma Llc Glucokinase activator compositions for the treatment of diabetes
HK1213780A1 (zh) * 2013-03-04 2016-07-15 Vtv治疗有限责任公司 穩定的葡萄糖激酶活化劑組合物
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
ME03420B (me) * 2014-12-19 2020-01-20 Aragon Pharmaceuticals Inc Postupak za pripremu jedinjenja diariltiohidantoina
CN105092770B (zh) * 2015-01-12 2017-03-29 上海中医药大学 一种筛选二肽基肽酶四抑制剂的方法
EP3307707B1 (en) 2015-06-15 2020-10-07 Bayer CropScience Aktiengesellschaft Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides
US10252977B2 (en) 2015-06-15 2019-04-09 Bayer Cropscience Aktiengesellschaft Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides
WO2018109002A1 (en) 2016-12-14 2018-06-21 Bayer Cropscience Aktiengesellschaft Active compound combinations
EP3335559A1 (en) 2016-12-14 2018-06-20 Bayer CropScience Aktiengesellschaft Active compound combinations
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
DK3804716T3 (da) 2018-05-31 2025-03-03 Hua Medicine Shanghai Ltd Farmaceutisk kombination, sammensætning og kombinationspræparat omfattende glucokinase-aktivator og sglt-2-inhibitor og fremgangsmåder til fremstilling og anvendelser deraf
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
EP4161640A4 (en) 2020-06-08 2024-01-17 vTv Therapeutics LLC Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910278A1 (en) 1990-02-16 1991-08-28 Ici Plc Heterocyclic compounds
US5612360A (en) 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
GB9315846D0 (en) 1993-07-30 1993-09-15 Isis Innovation Tumour inhibitors
US5795726A (en) 1996-11-12 1998-08-18 Millennium Pharmaceuticals, Inc. Methods for identifying compounds useful in treating type II diabetes
GB9806692D0 (en) 1998-03-27 1998-05-27 Pharmacia & Upjohn Spa Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents
HRP20010688B1 (en) 1999-03-29 2008-10-31 F. Hoffmann - La Roche Ag Glucokinase activators
US20030013633A1 (en) 1999-06-07 2003-01-16 Rima Kaddurah-Daouk Use of molecules that modulate an energy related associated state
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
BR0016631A (pt) 1999-12-23 2003-01-07 Novartis Ag Uso de agentes hipoglicêmico para tratar metabolismo de glicose depreciada
CN1209361C (zh) 2000-05-03 2005-07-06 霍夫曼-拉罗奇有限公司 含乙内酰脲的葡糖激酶激活剂
DE60134470D1 (de) 2000-05-08 2008-07-31 Hoffmann La Roche Para-amin substituierte phenylamid glukokinase activatoren
AU2001287600B2 (en) 2000-07-20 2006-07-13 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US6433188B1 (en) 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
AU2002352148A1 (en) 2001-06-29 2003-03-03 Abbott Gmnh & Co. Kg Bis-aryl thiazole derivatives
WO2003047626A1 (en) 2001-12-03 2003-06-12 Novo Nordisk A/S Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes
RU2374236C2 (ru) 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
EP1496052B1 (en) 2002-03-26 2009-08-05 Banyu Pharmaceutical Co., Ltd. Novel aminobenzamide derivative
WO2004026226A2 (en) 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
GB0216097D0 (en) 2002-07-11 2002-08-21 Univ London Treatment of proliferative disorders
WO2004028339A2 (en) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
JP2006509774A (ja) 2002-10-03 2006-03-23 ノバルティス アクチエンゲゼルシャフト 2型糖尿病の処置において有用なグルコキナーゼアクチベーターとしての置換(チアゾール−2−イル)−アミドまたはスルホンアミド
CA2499329C (en) 2002-10-03 2009-04-21 F. Hoffmann-La Roche Ag Indole-3-carboxamides as glucokinase (gk) activators
US20050202559A1 (en) 2002-10-29 2005-09-15 Scott Pownall Cancer treatment by metabolic modulations
JP4716734B2 (ja) 2003-01-06 2011-07-06 イーライ リリー アンド カンパニー グルコキナーゼ活性化物質としての置換されたアリールシクロプロピルアセトアミド
JP4621198B2 (ja) 2003-02-11 2011-01-26 プロシディオン・リミテッド トリ(シクロ)置換アミドグルコキナーゼ活性化化合物
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
US7179613B2 (en) 2003-05-05 2007-02-20 Vanderbilt University Methods of screening for a candidate modulator of glucokinase
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
WO2005052132A2 (en) 2003-11-24 2005-06-09 Exelixis, Inc Mbms as modifiers of branching morphogenesis and methods of use
EP1532980A1 (en) 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
GB0328178D0 (en) * 2003-12-05 2004-01-07 Astrazeneca Ab Compounds
CN1960995B (zh) 2004-04-02 2010-12-08 诺瓦提斯公司 作为葡糖激酶活化剂、可用于治疗ⅱ型糖尿病的磺酰胺-噻唑并吡啶衍生物
AU2005235798A1 (en) 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
US20080026987A1 (en) 2004-06-17 2008-01-31 Novo Nordisk A/S Use of Liver-Selective Glucokinase Activators
AU2005258021B2 (en) 2004-06-17 2008-12-18 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure and paroxysmal disorders
MX2007001650A (es) 2004-08-12 2007-07-13 Prosidion Ltd Fenilacetamidas substituidas y su uso como activadores de glucocinasa.
GB0418058D0 (en) 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
EP1789029A2 (en) 2004-08-30 2007-05-30 Interstitial Therapeutics Methods and compositions for the treatment of cell proliferation
JP4974057B2 (ja) 2005-01-31 2012-07-11 味の素株式会社 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物
WO2007001928A2 (en) 2005-06-22 2007-01-04 Merck & Co., Inc. Targets for inhibiting hcv replication
US7565029B2 (en) * 2005-07-08 2009-07-21 Seiko Epson Corporation Method for determining camera position from two-dimensional images that form a panorama
RU2420525C2 (ru) 2005-07-11 2011-06-10 Мицубиси Танабе Фарма Корпорейшн Производные оксимов и их получение
RU2008112184A (ru) 2005-08-31 2009-10-10 Астеллас Фарма Инк. (Jp) Производное тиазола
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
US20080293741A1 (en) 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
CA2628486A1 (en) * 2005-11-03 2007-05-10 Prosidion Ltd. Tricyclo substituted amides
WO2007061923A2 (en) 2005-11-18 2007-05-31 Takeda San Diego, Inc. Glucokinase activators
JP2009520825A (ja) 2005-12-20 2009-05-28 武田薬品工業株式会社 グルコキナーゼ活性剤
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
WO2007115968A2 (en) 2006-04-12 2007-10-18 F. Hoffmann-La Roche Ag Process for the preparation of a glucokinase activator
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
US7842713B2 (en) 2006-04-20 2010-11-30 Pfizer Inc Fused phenyl amido heterocyclic compounds
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
WO2008079787A2 (en) 2006-12-20 2008-07-03 Takeda San Diego, Inc. Glucokinase activators
US8138185B2 (en) 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
WO2008153814A2 (en) 2007-05-29 2008-12-18 President And Fellows Of Harvard College Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof
WO2009022179A2 (en) 2007-08-14 2009-02-19 Astrazeneca Ab Glucokinase activators in the treatment of osteoarthritis
TWI445707B (zh) 2008-05-16 2014-07-21 Takeda California Inc 葡萄糖激酶活化劑
US20130281708A1 (en) 2010-03-18 2013-10-24 Takeda California, Inc. Process for the Production of 2-Amino-5-Fluorothiazole
JP2013544787A (ja) 2010-10-13 2013-12-19 タケダ カリフォルニア インコーポレイテッド アザインダゾール誘導体の調製方法

Similar Documents

Publication Publication Date Title
JP2011520915A5 (enExample)
US10577367B2 (en) IRAK4 inhibiting agents
US9790210B2 (en) N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
CA2835835C (en) Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
EP2549875B1 (en) Soluble guanylate cyclase activators
JP6109192B2 (ja) ピリダジンアミド化合物及びsyk阻害剤としてのそれらの使用
AU2002341921B8 (en) Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5
JP5878178B2 (ja) 1,2,4−トリアジン−6−カルボキサミド誘導体
EP1835934A2 (en) Enzyme modulators and treatments
SI2933252T1 (en) Kinase inhibitors as apoptotic signal regulators
RU2018123779A (ru) Новые соединения
US11173145B2 (en) Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
ME02100B (me) Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora
AU2006315334A1 (en) Aminopyrimidines useful as kinase inhibitors
WO2014026327A1 (en) 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
TW201202221A (en) Nitrogen containing heteroaryl compounds
JP2014521651A (ja) 特定のキヌレニン−3−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
MX2008015648A (es) Pirazinonas como inhibidores de proliferacion celular.
TW200817375A (en) Compounds and compositions as ITPKB inhibitors
JP2018506571A (ja) Rho関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物
TW200526641A (en) Amidopyrazole derivatives
JP6176244B2 (ja) 芳香族複素環誘導体及び医薬
JP2006045118A (ja) 新規ピラゾロキノロン誘導体
JP2014198693A (ja) 免疫疾患の予防及び/又は治療剤
EP4565575A1 (en) Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof